You are here

Drugmakers turn focus to fatty liver, hepatitis B treatments

The drugs on clinical trial, once approved, could reach annual sales of as much as US$10b, say industry analysts

Some of the drugs will address advanced fibrosis and cirrhosis, which are the scarring liver diseases cause without effective treatments.

New York

NOW that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than US$30